A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study
Authors:
- Peter G RosePRPeter G Rose
- John A BlessingJBJohn A Blessing
- Harrison G BallHBHarrison G Ball
- James HoffmanJHJames Hoffman
- David WarshalDWDavid Warshal
- Koen DeGeestKDKoen DeGeest
- David H MooreDMDavid H Moore
- 1 February 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 88 (2) , 130-135
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian CancerJNCI: Journal of the National Cancer Institute, 1995
- Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublinesin vitroInvestigational New Drugs, 1994
- Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP–cell viability assayAnti-Cancer Drugs, 1994
- Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenograftsEuropean Journal of Cancer, 1994
- In vitro cytotoxic activity of taxol' and taxotere on primary cultures and established cell lines of human ovarian cancerStem Cells, 1993
- Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cellsAnti-Cancer Drugs, 1992
- Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and-resistant human ovarian carcinoma cell linesCancer Chemotherapy and Pharmacology, 1992
- Relationships between the structure of taxol analogs and their antimitotic activityJournal of Medicinal Chemistry, 1991
- Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of TaxolJNCI: Journal of the National Cancer Institute, 1991
- Promotion of microtubule assembly in vitro by taxolNature, 1979